PUBLISHER: Grand View Research | PRODUCT CODE: 1611239
PUBLISHER: Grand View Research | PRODUCT CODE: 1611239
The global self-testing market size is expected to reach USD 18.32 billion by 2030, registering a CAGR of 8.40% from 2025 to 2030, according to a new report by Grand View Research, Inc. This is owing to the increasing health awareness, convenience, cost-effectiveness, technological advancements, the rising prevalence of chronic diseases, remote healthcare trends, and the need for timely and accessible health information. According to the WHO, noncommunicable diseases cause 41 million deaths every year across the globe.
Moreover, innovations in portable and user-friendly devices, integration with smartphones and digital platforms, enhanced accuracy and sensitivity of testing methods, and the development of rapid diagnostic tools have all contributed to making self-testing more accessible, reliable, and convenient for consumers. For instance, in March 2023, Lucira Health, Inc. announced the launch of the COVID-19 & Flu Home Test. The test is an all-in-one combination test capable of delivering results in 30 minutes. Such advancements are anticipated to expand the market's reach and acceptance over the forecast period.
Furthermore, COVID-19 has accelerated the adoption of self-testing technologies and highlighted the importance of self-diagnostic tools in managing public health crises. Regulatory bodies expedited approvals for various self-testing products to meet the increasing demand, contributing to the market's growth. For instance, in February 2021, Siemens Healthineers received approval from the German Federal Office for Drugs and Medical Devices for its CLINITEST Rapid COVID-19 Antigen Self-Test, enabling its self-administration in Germany.
Key players in the market for self-testing, such as Johnson & Johnson, B. Braun Holding GmbH, Piramal Enterprises, Cardinal Health, and BD, among others, are adopting various strategies to enhance their product penetration and expand their customer base. For instance, in December 2022, Roche Holding partnered with Pfizer on a U.S. campaign. The goal of this campaign is to create awareness regarding COVID-19 treatment and testing.